LSTA LISATA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 320017 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-90.7%
TTM net income YoY5.9%
TTM EPS YoY11.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-22,043.0%
Net margin-17,159.0%
FCF margin-21,662.0%
EBITDA margin-22,020.0%
Returns
ROE-137.2%
ROA-5.1%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets8.8%
Debt / equity0.00x
Current ratio14.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.26x
Accruals ratio1.3%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $170,000 | $1.00M | $0 | $0 | — |
| R&D expense | $7.95M | $11.33M | $12.73M | $13.07M | $17.58M |
| SG&A expense | $10.43M | $12.07M | $12.97M | $14.14M | $11.47M |
| Operating income | -$18.21M | -$22.41M | -$25.71M | -$57.60M | -$29.05M |
| Pretax income | -$17.55M | -$20.78M | -$23.17M | -$56.70M | -$28.97M |
| Income tax | -$962,000 | -$798,000 | -$2.33M | -$2.48M | -$1.51M |
| Net income | -$16.59M | -$19.98M | -$20.84M | -$54.23M | -$27.47M |
| EBITDA | -$18.06M | -$22.23M | -$25.52M | -$57.53M | -$29.00M |
| EPS (basic) | -1.91 | -2.40 | -2.58 | -10.47 | -7.45 |
| EPS (diluted) | -1.91 | -2.40 | -2.58 | -10.47 | -7.45 |
| Weighted avg. shares (diluted) | 8.69M | 8.33M | 8.07M | 5.18M | 3.69M |
| Balance sheet | |||||
| Cash & equivalents | $15.96M | $16.21M | $22.59M | $32.15M | $24.65M |
| Receivables | $0 | $900,000 | $0 | — | — |
| Current assets | $17.70M | $34.58M | $53.92M | $71.88M | $96.18M |
| PP&E, net | $18,000 | $72,000 | $175,000 | $296,000 | $62,000 |
| Goodwill | $0 | — | — | — | — |
| Intangibles | $0 | $192,000 | $263,000 | $334,000 | $0 |
| Total assets | $17.74M | $35.00M | $54.69M | $73.03M | $97.01M |
| Current liabilities | $3.07M | $5.61M | $6.59M | $6.38M | $4.52M |
| Total liabilities | $3.14M | $5.68M | $6.80M | $6.71M | $5.01M |
| Shareholders' equity | $14.86M | $29.57M | $48.15M | $66.58M | $92.25M |
| Shares outstanding | 8.83M | 8.41M | 8.15M | 7.87M | 3.99M |
| Cash flow statement | |||||
| Operating cash flow | -$15.95M | -$19.36M | -$20.03M | -$21.17M | -$22.25M |
| Capital expenditure | $28,000 | $0 | $0 | $285,000 | $60,000 |
| Free cash flow | -$15.98M | -$19.36M | -$20.03M | -$21.45M | -$22.30M |
| Investing cash flow | $15.09M | $13.23M | $10.10M | $28.91M | -$54.90M |
| Financing cash flow | $599,000 | -$206,000 | $385,000 | -$224,000 | $85.28M |
| Depreciation & amortization | $146,000 | $174,000 | $189,000 | $69,000 | $55,000 |
| Stock-based compensation | $1.23M | $1.65M | $2.04M | $2.64M | $2.00M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.